Drugs online research references
Kidney Int Suppl. 1992 May;36:S100-5.
Effects of chronic felodipine treatment on renal function and morphology in SHR.
Nordlander M, Havu N.
Department of Pharmacology, Astra Hassle Research Laboratories, Molndal, Sweden.
To investigate if blood pressure reduction per se may prevent progressive renal disease in aging spontaneously hypertensive rats (SHR), 15-month-old SHR were treated with the calcium antagonist felodipine, with the beta-blocker metoprolol or with the combination for six months. The combined regimen caused the greatest blood pressure reduction over time, metoprolol caused the least, while felodipine had an intermediate effect. At the end of treatment, urinary protein excretion and endogenous creatinine clearance were determined in rats kept in individual metabolic cages. At autopsy, the kidneys were histologically examined and indices of chronic progressive nephrosis and glomerular sclerosis were determined. A positive correlation was found between urinary protein excretion and glomerular sclerosis. Glomerular sclerosis was low in the groups of rats with high endogenous creatinine clearance. In both groups treated with felodipine, glomerular sclerosis and urinary protein excretion were significantly reduced compared to untreated controls. These results illustrate that the calcium antagonist felodipine attenuates proteinuria and glomerular sclerosis in aging SHR. The blood pressure reduction may be of major importance in this respect, although a direct action on the sclerotic process within the glomeruli may also contribute.
online pharmacy ref source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1614058&dopt=Abstract
Clin Exp Hypertens. 1998 Nov;20(8):833-46.
Cost-effectiveness of felodipine-metoprolol (Logimax) and enalapril in the treatment of hypertension.
Andersson F, Kartman B, Andersson OK.
Health Economics & Quality of Life, Astra Draco AB, Lund, Sweden.
We present results from a Swedish retrospective cost-effectiveness analysis of felodipine-metoprolol (Logimax) and enalapril in hypertension. In the 8-week trial, the average reduction of diastolic blood pressure (DBP) and the share of patients reaching target DBP were both significantly greater in the felodipine-metoprolol group. Cost of treatment (costs of drugs and physician visits) was somewhat higher in the felodipine-metoprolol group. After 8 weeks, an extra 4.8 mmHg reduction and an additional 22% of patients reaching target DBP were achieved with felodipine-metoprolol at the extra cost of SEK 19 (Swedish kronor, $US I=SEK 7.90). The incremental cost per mmHg reduction and per patient reaching target DBP was calculated at SEK 4 and SEK 86, respectively. Average cost-effectiveness ratios showed that the costs per mmHg reduction and per patient reaching target DBP after 8 weeks were 40 and 34% lower in the felodipine-metoprolol group, respectively. In conclusion, felodipine-metoprolol is cost-effective in the treatment of hypertension.
online pharmacy ref source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9817605&dopt=Abstract
J Hum Hypertens. 1988 Jun;2(1):27-31.
The effects of combining felodipine and metoprolol in moderate to severe hypertension--a one year study.
Chow J.
Department of Medicine, Queen Mary Hospital, Hong Kong.
A dose titration study was performed using felodipine, a new calcium antagonist, in Chinese patients with essential hypertension inadequately controlled by metoprolol alone (DBP greater than 95 mmHg). BP and pulse rate were recorded at rest and during treadmill exercise. Nineteen patients completed the six weeks' dose titration phase (2.5-5-10 mg twice daily) of whom 17 were followed for one year. A single 2.5 mg dose of felodipine produced a rapid and pronounced antihypertensive response with pre-exercise supine BP falling from a mean 168/104 to 146/92 mmHg) (P less than 0.001). The SBP during exercise was reduced from 206 to 185 mmHg (P less than 0.001). After 6 weeks treatment the supine BP had fallen to 132/85 mmHg (P less than 0.001) and the SBP during exercise to 169 mmHg (P less than 0.001). Six patients received 2.5 mg twice daily, eight patients 5 mg twice daily and three patients 10 mg twice daily. The effects, both at rest and during exercise, were maintained for at least 12 hours after dosing. The pulse rate was unaffected by felodipine therapy apart from a small transient increase following the first dose. Sixteen patients achieved the target DBP of 90 mmHg measured 12 hours after dosing and only one patient still had a DBP greater than 95 mmHg. After one year the mean supine BP had fallen slightly further to 128/82 mmHg. One patient was withdrawn due to palpitations. Felodipine was otherwise well tolerated.(ABSTRACT TRUNCATED AT 250 WORDS)
online pharmacy ref source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3236315&dopt=Abstract
online pharmacies ||
Hair Million herbal formula for hair loss and hair growth ||
Amoxicillin ||
Tramadol ||
Paxil ||
Rx Drugs USA, Prescription Drugs Online Pharmacy ||
Zithromax ||
online pharmacy ||
Antibiotics and prescription medications online literature ||
Antibiotics